ClinicalTrials.Veeva

Menu

Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial

Vanderbilt University Medical Center logo

Vanderbilt University Medical Center

Status

Begins enrollment in 1 month

Conditions

Stage II Lung Cancer
Stage I Lung Cancer

Treatments

Procedure: Robotic Bronchoscopy
Procedure: Resection
Other: Electronic Health Record Review
Procedure: Bronchoscopy with Biopsy
Procedure: Chest Radiography
Procedure: Computed Tomography
Procedure: Biospecimen Collection
Procedure: Cryosurgery

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT06593106
P30CA068485 (U.S. NIH Grant/Contract)
NCI-2024-07299 (Registry Identifier)
VICC-VCTHO24099

Details and patient eligibility

About

This clinical trial studies side effects and best treatment time of cryodevitalization in treating patients with early stage (stage I or stage II) lung cancer. Cryodevitalization is a type of cryosurgery that uses a flexible probe (cryoprobe) to kill tumor cells by freezing them. It is delivered at the time of standard diagnostic robotic bronchoscopy. Using cryodevitalization may be safe, tolerable and/or effective in treating patients with early stage lung cancer.

Full description

PRIMARY OBJECTIVE:

I. To identify the maximum tolerated dose (MTD) for cryodevitalization cycle duration.

OUTLINE: This is a dose-escalation study.

Patients undergo 3 freeze-thaw cycles of cryodevitalization over 30 seconds or 3, 5, or 7 minutes each during standard of care robotic bronchoscopy with biopsy on study. Patients then undergo standard of care surgical resection on study. Patients also undergo a chest radiography (x-ray) on study as well as computed tomography (CT) and tissue sample collection throughout the study.

After completion of study treatment, patients are followed up at 3 and 7 days and are then followed as clinically required per standard of care for 24 months.

Enrollment

30 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a single pulmonary nodule with a size less than two centimeters (average long and short axis) confirmed as lung cancer intraprocedurally (rapid on-site evaluation with pathology assessment) without evidence of mediastinal involvement who require nodule biopsy prior to proceeding with surgical resection
  • Nodules must be located in the outer 2/3 of the periphery of the lung, greater than 10 mm from the pleura and from large blood vessels or mediastinal structures to avoid injury to other visceral organs
  • Patients deemed to have a surgical resection treatment option based on preoperative staging computed tomographic (CT), postoperative predicted forced expiratory volume in 1 second (FEV1) > 40% and evaluation of medical comorbidities after discussion at multidisciplinary tumor board
  • Age > 18 years old

Exclusion criteria

  • Target nodule is within the International Association for the Study of Lung Cancer (IASLC) "central zone" (including bronchial tree, major vessels, heart, esophagus, spinal cord and phrenic & laryngeal nerves), or are < 10 mm from the pleura
  • Patients with an expected survival less than 6 months
  • Patients with endobronchial lesions, concerning for malignancy, visualized during the initial bronchoscopic evaluation of the airways
  • Patients with medically uncorrectable coagulopathy: abnormal platelet count < 100 × 10^9/L or an international normalized ratio > 1.5
  • Patients with known pulmonary hypertension (PASP [pulmonary artery systolic pressure] > 50mmHg)
  • Patients who are currently prescribed anticoagulants, clopidogrel, or other platelet aggregation inhibitors
  • Patients with medical comorbidities deemed high-risk for surgical resection
  • Pregnant women
  • Inability to provide informed consent

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

30 participants in 1 patient group

Treatment
Experimental group
Description:
Patients undergo 3 freeze-thaw cycles of cryodevitalization over 30 seconds or 3, 5, or 7 minutes each during standard of care robotic bronchoscopy with biopsy on study. Patients then undergo standard of care surgical resection on study. Patients also undergo a chest x-ray on study as well as CT and tissue sample collection throughout the study.
Treatment:
Procedure: Cryosurgery
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Chest Radiography
Procedure: Bronchoscopy with Biopsy
Other: Electronic Health Record Review
Procedure: Resection
Procedure: Robotic Bronchoscopy

Trial contacts and locations

1

Loading...

Central trial contact

Vanderbilt-Ingram Services for Timely Access

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems